Abstract
Purpose :
To determine the efficacy and complications of the Susanna glaucoma drainage device (SGDD) implant in refractory glaucoma.
Methods :
Retrospective study. Medical records from consecutive glaucoma patients followed in a private clinical practice were included in the study. All patients that had undergone SGGD implant surgery from the period of September 2016 to July 2019 were included. All surgeries were done by the same surgeon (RSJ). Primary outcome was surgical failure, defined as IOP>18 mmHg and/or less than 20% IOP reduction from baseline, IOP less than 5 mmHg, reoperation for glaucoma need of implant removal or loss of light perception vision. Secondary outcomes included mean IOP, use of supplemental medical therapy, and complications.
Results :
22 eyes were analyzed. Mean patient age was 63 ± 15 (range: 27 to 87) years. Mean IOP decreased from 23 ± 7 mmHg to 11 ± 8 mmHg (P<0.001, paired t-test) at an average of 18 ± 9 months after the tube implant. The mean SD number of glaucoma medications was reduced from 3.3 ± 1 to 1.5 ± 1.2 at the last postoperative visit (P<0.01, paired t-test). No early postoperative complications occurred. There was one case of persistent hypotony that was solved with tube ligature. Failure due to high IOP occurred in two cases. There was no extrusion or erosion of the tube or the plate.
Conclusions :
The SGDD presented a 13.6% failure rate with very few complications, being an efficient and safe alternative for refractory glaucoma.
This is a 2021 ARVO Annual Meeting abstract.